ProLynx
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
135 Mississippi St, San Francisco, Calif...Phone Number
(415) 552-5306Website
www.prolynxinc.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About ProLynx
Prolynx is a biotechnology company dedicated to developing ultra-long-acting medicines for obesity and related metabolic diseases. The companys proprietary portfolio is built on a proven half-life extension technology engineered to support more consistent, long-term treatment with improved tolerability and optimized pharmacokinetics.Explore more
ProLynx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ProLynx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at ProLynx
Funding: Get notified immidiatlly once ProLynx has new funding data
Check if ProLynx has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if ProLynx had a recent Job posting/layoffs
ProLynx, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when ProLynx launches new products
Check out if ProLynx is spiking on competitors!
Earning: See what the market has to say on ProLynx recently announced quarterly report
Recommended Actions
Find VP level buyers at ProLynx
Find more new buyers
Compare Similar Companies to ProLynx
Compare insights from companies similar to ProLynx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ProLynx is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ProLynx is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ProLynx.
ProLynx financials insights
Gather financial insights about ProLynx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2021
Debt
$207K
2025
Series A
$70M
ProLynx Tech Stack
A closer look at the technologies used by ProLynx
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Lateral Move
Executive Move
Executive Moves, Lateral Move
Left Company
Executive Move
Executive Moves, Left Company
Funding
Funding
New Hire
Executive Move
ProLynx News & Media
Prolynx Secures $70 Million Series A to Advance Portfolio of Ultra-Long-Acting Obesity Candidates and Appoints Chris Boulton as Chief Executive Officer
Prolynx Secures $70 Million Series A to Advance Portfolio of Ultra-Long-Acting Obesity Candidates and Appoints Chris Boulton as Chief Executive OfficerProLynx Announces Publication of Its Once Monthly Semaglutide in the Proceedings of the National Academy of Sciences
Single injection of ProLynx long-acting semaglutide produced 20% weight loss in diet-induced obese mice, which is comparable to multiple semaglutide injections over the same period SAN FRANCISCO, Dec. 2, 2024 /PRNewswire/ -- ProLynx Inc., a biotechnology company developing proprietary...ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing
SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced the use of their technology to create a long-acting semaglutide that can be administered once monthly. The ProLynx technology involves tethering a therapeutic to hydrogel microspheres via linkers with tunable, pre-programmed release rates. Semaglutide is a peptide GLP-1 agonist that is the active ingredient in the Novo Nordisk blockbuster drugs Ozempic® and Wegovy®; Ozempic® is used to treat Type 2 diabetes, whereas WeProLynx announces initiation of Phase II clinical trial of its DNA-damaging agent PLX038 in patients with platinum-resistant Ovarian Cancer at the Mayo Clinic
SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum-resistant ovarian cancer at the Mayo Clinic. Mayo Clinic investigators Drs. Andrea E. Wahner Hendrickson and Scott H. Kaufmann are conducting the trial.
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding ProLynx
Sign Up For FreeTo access detailed company insights
Prolynx is a biotechnology company dedicated to developing ultra-long-acting medicines for obesity and related metabolic diseases. The companys proprietary portfolio is built on a proven half-life extension technology engineered to support more consistent, long-term treatment with improved tolerability and optimized pharmacokinetics.... Read More
